Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 54

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 16
Chunk 54
---
 64

        $
        3,555.83

        5.8

        Exercisable at December 31, 2024

        64

        $
        3,555.83

        5.8

      For the year ended December 31, 2023, the weighted-average Black-Scholes value per stock option issued during 2023 was $516.21. The fair value of the stock options was estimated using the Black-Scholes option pricing model with the following weighted-average assumptions: 

        Volatility

        144.2
        %

        Expected term (years)

        5.04

        Risk-free interest rate

        3.60
        %

        Expected dividend yield

        0.0
        %
       
       Expected volatility is based on the historical volatility of shares of the Company’s common stock. In determining the expected term of stock options, the Company uses the “simplified” method. Under this method, the expected term is presumed to be the midpoint between the average vesting date and the end of the contractual term. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the stock options in effect at the time of the grants. The dividend yield assumption is based on the expectation of no future dividend payments by the Company. In addition to assumptions used in the Black-Scholes model, the Company reduces stock-based compensation expense based on actual forfeitures in the period that each forfeiture occurs.Stock-Based Compensation ExpenseFor the years ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense for the period indicated as follows: 

        Year EndedDecember 31,

        2024

        2023

        General and administrative:

        RSU awards
         
        $
        97,077

        $
        89,533

        Stock Options

        58,857

        56,204

        General and administrative stock-based compensation expense

        155,934

        145,737

        Research and development:

        RSU awards

        7,759

        7,592

        Stock Options

        5,157

        2,392

        Research and development stock-based compensation expense

        12,916

        9,984

        Total stock-based compensation expense
         
        $
        168,850

        $